OSMT Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 jan 2022 @ 06:00):

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary...

Stats
Dagens volum	296 322
Gjennomsnittsvolum	594 359
Markedsverdi	110.18M
EPS	$-0.280 ( 2021-11-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.694
ATR14	$0.0990 (8.92%)

Insider Trading

Date	Person	Action	Amount	type
2021-01-24	Klein Christopher	Sell	9 605	Ordinary Shares
2020-05-20	Cowan Gregory L	Buy	38 716	Ordinary Shares
2020-05-21	Cowan Gregory L	Sell	11 112	Ordinary Shares
2020-01-28	Schaub James	Sell	9 197	Ordinary Shares
2019-01-24	Weiss Fred G	Buy	34 403	Ordinary Shares

INSIDER POWER
0.00
Last 6 transactions
Buy: 177 968 \| Sell: 29 914

Volum Korrelasjon

Lang: -0.10 (neutral)

Kort: 0.02 (neutral)

Signal:(45.447) Neutral

Osmotica Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
GOODM	0.927
OPK	0.842
CHKEL	0.827
SY	0.81
MHLD	0.804

10 Mest negative korrelasjoner
CFBK	-0.899
DOX	-0.871
ARDX	-0.87
GLBZ	-0.865
CERC	-0.853
FATP	-0.852
IMTX	-0.852
PBPB	-0.848
CRVS	-0.845
ECOR	-0.843

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Osmotica Pharmaceuticals Korrelasjon - Valuta/Råvare

-0.70
( moderate negative )

-0.85
( strong negative )

0.26
( neutral )

-0.52
( weak negative )

-0.60
( weak negative )

0.62
( weak )

Osmotica Pharmaceuticals Økonomi

Annual	2022
Omsetning:	$49.72M
Bruttogevinst:	$40.27M (80.98 %)
EPS:	$-0.580

FY	2022
Omsetning:	$49.72M
Bruttogevinst:	$40.27M (80.98 %)
EPS:	$-0.580

FY	2020
Omsetning:	$177.88M
Bruttogevinst:	$103.40M (58.13 %)
EPS:	$-1.520

FY	2019
Omsetning:	$240.03M
Bruttogevinst:	$128.40M (53.49 %)
EPS:	$-5.17

Financial Reports:

No articles found.

Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.